廣生堂(300436.SZ)半年度實現淨利潤1133.55萬元 同比增長161.95%
格隆匯8月25日丨廣生堂(300436.SZ)發佈2019年半年度報告，報告期內，公司實現營業收入2.15億元，同比增長32.35%；歸屬於上市公司股東的淨利潤1133.55萬元，同比增長161.95%；歸屬於上市公司股東的扣除非經常性損益後的淨利潤54.95萬元，比上年同期下降86.11%；基本每股收益0.081元。
堅定不移向創新藥企業轉型，新藥階段性成果突出。2019年3月，公司立項乙肝治療創新藥GST-HG121，該項目現已確定臨牀前候選化合物(PCC)，處於臨牀試驗(IND)申報前的準備階段；2019年4月，非酒精性脂肪肝病及肝纖維化可逆轉全球創新藥GST-HG151獲得國家藥監局臨牀批件；2019年7月，乙肝治療創新藥GST-HG131的Pre-IND(臨牀註冊前)會議申請獲得受理；2019年7月，新型肝癌靶向藥物GST-HG161首例c-MET陽性患者成功入組，正式開展I期臨牀；2019年8月，乙肝治療全球創新藥GST-HG141臨牀試驗申請獲得受理。通過持續的研發投入，公司創新藥戰略得到進一步落實，已在創新藥市場搶佔了一定先機
以仿哺創，繼續推動仿製藥研發，創造新的利潤增長點。2019年7月，枸櫞酸西地那非片完成與原研藥品的體外質量與體內療效的一致性評價且其生產註冊申請獲得國家藥監局受理，進入生產審評審批階段，有望進一步豐富了公司生產線；公司富馬酸替諾福韋艾拉酚胺(TAF)和丙肝藥物索磷布韋均已完成人體生物等效性臨牀試驗，正進行生產註冊申請前的臨牀總結和藥學研究資料彙總工作。
內生髮展，外延助力，不斷夯實核心競爭力。報告期內，公司積極應對醫改政策，對內進一步規範管理，強化成本管控，降本增效，公司恩替卡韋膠囊和阿德福韋酯片分別通過一致性評價，進一步提升公司的市場競爭力；持續對中興藥業進行整合優化，導入上市公司的營銷資源和管理經驗，提升其產品的市場佔有率和運營效益，在報告期內中興藥業貢獻營業收入7439.06萬元，合併報表淨利潤427.66萬元。同時，公司積極尋找和佈局能為公司帶來盈利增長點的新品種、新業態、新領域，持續提高企業核心競爭力和盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
